Completed PHASE1 INTERVENTIONAL 1-arm NCT00625456

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors

Sponsor: Jennerex Biotherapeutics

Conditions Lung Cancer Melanoma Renal Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck

Interventions Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Updated 7 times since 2017 Last updated: Nov 30, 2015 Started: Jun 30, 2008 Primary completion: Apr 30, 2010 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Lung Cancer and Melanoma, this trial is completed. The trial is conducted by Jennerex Biotherapeutics and has accumulated 7 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jennerex Biotherapeutics

Data source: SillaJen, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials